BioCryst (BCRX) Soars 10.8% on Swing to Profits

We recently published 10 Stocks Ending February With a Bang. BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) was one of the best performers on Friday.

BioCryst surged by 10.76 percent on Friday to close at $8.75 apiece, as investor sentiment was bolstered by its swing to profitability for the first time last year.

In an updated report, BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) said that it swung to a net income of $263.86 million last year from an $88.88 million net loss in 2024. Total revenues soared by 94 percent to $874.8 million from $450.7 million year-on-year, helped by the successful $243.3 million sale of its European Orladeyo business to Neopharmed Gentili. Orladeyo is a prescription oral medicine for preventing hereditary angioedema attacks in adults and children 12 years and older.

In the fourth quarter alone, BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) incurred a $245.8 million net income, reversing a $26.79 million net loss in the same period a year earlier. Total revenues more than tripled to $406.5 million from $131.5 million year-on-year.

“2025 was fundamentally transformative for BioCryst. We achieved full-year profitability for the first time in the company’s history, driven by strong commercial execution that delivered the highest level of new patient prescriptions in the US since the initial launch of ORLADEYO, even as the treatment landscape continued to evolve,” said BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) President and CEO Charlie Gayer.

For this year, the company is targeting to generate total revenues between $635 million and $660 million, of which around $625 million to $645 million will come from sales from Orladeyo.

While we acknowledge the potential of BCRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. Follow Insider Monkey on Google News.